(Circulation. 1997;95:69-75.)
© 1997 American Heart Association, Inc.
Articles |
Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men
Prospective Results From the Quebec Cardiovascular Study
the Lipid Research Center, CHUL Research Center (B.L., A.T., S.M., B.C., P.J.L., J.-P.D.) and the Department of Medicine, University of Montreal (G.R.D.), Quebec, Canada.
Correspondence to Jean-Pierre Despres, PhD, Director and Professor, Lipid Research Center, CHUL Research Center, 2705 Laurier Blvd, Ste-Foy, Quebec, G1V 4G2 Canada. E-mail jpierre.despres@crchul.ulaval.ca.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background Case-control studies have reported that patients with ischemic heart disease (IHD) have a higher proportion of small, dense LDL particles than do healthy control subjects. The extent to which the risk attributed to small LDL particles may be independent of concomitant variations in plasma lipoprotein-lipid concentrations remains to be clearly determined, however, particularly through prospective studies.
Methods and Results Baseline characteristics were obtained in 2103 men initially free of IHD, among whom 114 developed IHD during a 5-year follow-up period. These 114 case patients were matched with healthy control subjects for age, body mass index, smoking habits, and alcohol intake. LDL peak particle diameter (PPD) was measured a posteriori in 103 case-control pairs by nondenaturing gradient gel electrophoresis of whole plasma. Conditional logistic regression analysis of the case-control status revealed that men in the first tertile of the control LDL-PPD distribution (LDL-PPD
25.64 nm) had a 3.6-fold increase in the risk of IHD (95% CI, 1.5 to 8.8) compared with those in the third tertile (LDL-PPD>26.05 nm). Statistical adjustment for concomitant variations in LDL cholesterol, triglycerides, HDL cholesterol, and apolipoprotein B concentrations had virtually no impact on the relationship between small LDL particles and the risk of IHD.
Conclusions These results represent the first prospective evidence suggesting that the presence of small, dense LDL particles may be associated with an increased risk of subsequently developing IHD in men. Results also suggest that the risk attributed to small LDL particles may be partly independent of the concomitant variation in plasma lipoprotein-lipid concentrations.
Key Words: apolipoproteins • lipids • heart diseases • risk factors • lipoproteins
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although the association between LDL cholesterol levels and IHD is well accepted, a relatively high proportion of patients with IHD have plasma LDL cholesterol levels in the normal range.1 LDL particles are heterogeneous with respect to size, density, composition, and physicochemical properties.2 3 4 5 Several approaches have been used to characterize LDL particles. Using gradient gel electrophoretic analysis of isolated LDL, Austin et al6 dichotomized LDL particles into two distinct LDL phenotypes: pattern B, with a predominance of small, dense LDL particles, and pattern A, with a higher proportion of large, more buoyant LDL particles. Others have developed a global score representative of the distribution of LDL particle size and density values.7 8 9 10 Irrespective of the approach used to characterize LDL particles and of the case definition, dense LDL particles were more prevalent among IHD case patients than among IHD-free control subjects.10 11 12 13 In some instances, the relationship between the dense LDL phenotype and IHD remained significant after control for age, degree of obesity, and sex.14 15
An increased proportion of small, dense LDL particles has also been associated with marked alterations in plasma lipoprotein and lipid levels, such as elevated TG and apo B concentrations and reduced HDL cholesterol levels, all of which are highly predictive of an increased risk for IHD.8 10 13 14 15 16 Whether the increased IHD risk associated with the presence of small, dense LDL is independent of the concomitant variation in plasma lipid levels remains to be clearly established, particularly through prospective studies.17 The respective contributions of the dense LDL phenotype and of lipoprotein-lipid levels to the subsequent development of IHD were examined in a subsample of men involved in the prospective phase of the Quebec Cardiovascular Study. The LDL phenotype was determined by measurement of LDL-PPD in men initially free of clinical manifestations of IHD at entry, who eventually developed IHD over a 5-year follow-up. These men were compared with a group of matched control subjects who remained free of IHD during the same period.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population and Follow-up
The Quebec Cardiovascular Study cohort has been described in detail previously.18 19 Briefly, in 1973 a random sample of 4637 men 35 to 64 years old was recruited by use of the provincial electoral lists from seven counties of the Quebec metropolitan area for an evaluation of cardiovascular risk factors. Subsequent evaluations were performed at regular intervals, and data collected in 1985 were used as the baseline characteristics for the present prospective analyses. At the 1985 evaluation, 61% (n=2443) of the living cohort came to the lipid clinic in a fasting state for their evaluation. Among the 1557 other living potential participants, 10% could not be located, 19% showed up in a nonfasting state, and 71% either refused to participate or were evaluated in a nonfasting state at their homes by nurses of the project. Analyses of data collected in 1973 revealed that the age distribution of the 2443 participating men in 1985 was representative of the original cohort. In 1990 to 1991, all participants were contacted by mail and invited to answer a short standardized questionnaire on smoking habits, medication use, and history of cardiovascular diseases and diabetes mellitus. For those who reported such diseases and those who had died, hospital charts were reviewed. Telephone calls were made to participants who did not answer a second letter or, if unsuccessful, to a close family member. Mortality and morbidity data were obtained in 99% and 96%, respectively, of the participants of the 1973 initial screening. No difference in the frequency of IHD mortality was observed between the participants and the nonparticipants.
Evaluation of Risk Factors
Data on demographic and lifestyle variables as well as medical history and medication were obtained in 1985 through a standardized questionnaire administered to each participant by trained nurses and further reviewed by a physician. Body weight and height were recorded. Resting blood pressure was measured after a 5-minute rest in a sitting position. The mean of two blood pressure measures taken 5 minutes apart was used in the analyses. The following data were compiled from the questionnaire: personal and family history of IHD and diabetes, smoking habits, alcohol consumption, and medication use. Diabetes was considered in men who self-reported the disease or who were treated with hypoglycemic agents. Only 2% of men were using hypolipidemic drugs in 1985, whereas 8% and 4% of men, respectively, were using ß-blockers and diuretics on a regular basis at the 1985 screening. Alcohol intake was computed from the type of beverage (beer, wine, and spirits) consumed in ounces per week and then standardized as absolute quantity, 1 oz of absolute alcohol being equivalent to 22.5 g of alcohol. Family history of IHD was considered positive if at least one parent and/or one sibling had a previous history of IHD.
Definition of IHD Events
The diagnosis of a first IHD event included typical effort angina, coronary insufficiency, nonfatal myocardial infarction, and coronary death. All myocardial infarction case patients met the criteria previously described,18 namely, diagnostic ECG changes alone or two of the following criteria: typical chest pain of 
20 minutes' duration, abnormal creatine kinase enzyme at least twice the upper limit of normal, or characteristic ECG changes. Coronary insufficiency was considered if typical retrosternal chest pain of at least 15 minutes' duration was associated with transient ischemic ECG changes but without significant elevation in levels of creatine kinase. Diagnoses of all myocardial infarctions and coronary insufficiency were confirmed by hospital charts. All ECGs were read by the same cardiologist, who was unaware of the participants' risk profile. The diagnosis of effort angina was based on typical symptoms of retrosternal squeezing or pressure-type discomfort occurring on exertion and relieved by rest and/or nitroglycerin. Criteria for the diagnosis of coronary deaths included confirmation from death certificates, or autopsy report confirming the presence of coronary disease and without evidence for noncardiac disease that could explain death. Myocardial infarction was considered fatal if death occurred within 4 weeks of the initial event or if it was diagnosed at autopsy. IHD-related deaths were confirmed from the Provincial Death Registry. Informed consent was obtained to review relevant hospital files. Autopsies were performed in about one third of deaths.
Pairing Procedures
From the sample of 2103 men without clinical evidence of IHD in 1985 and with a complete profile, 114 developed IHD during the 5-year follow-up that ended in September 1990.19 The 114 cases of IHD included 48 first cases of myocardial infarction, 51 cases of effort angina, and 15 IHD-related deaths. Each subject with confirmed IHD (case subject) was matched with a control subject selected among the remaining 1989 men who showed no clinical signs of IHD during follow-up.20 Subjects were matched on the basis of age, cigarette smoking, body mass index, and weekly alcohol intake. The mean within-pair differences for matching were 0.6 year, 0.2 kg/m2, and 0.2 oz/wk for age, body mass index, and alcohol intake, respectively. The mean within-pair difference for cigarette smoking was 0.3 cigarette per day. A total of 11 pairs of men were excluded because of the impossibility of measuring LDL size or because they could not be matched owing to extreme values of cigarettes smoked per day.
Laboratory Analyses
Twelve-hour fasting blood samples were obtained from an antecubital vein while participants were in a sitting posture. A tourniquet was used but was released before blood withdrawal into vacuum tubes (Vacutainer, Becton-Dickinson) containing EDTA. Plasma was separated from blood cells by centrifugation and was immediately used for lipid and apolipoprotein measurements. Aliquots of fasting plasma were frozen at the time of collection and were later used for the assessment of LDL size. Plasma cholesterol and TG levels were determined on an Auto Analyzer II (Technicon Instruments Corp) as previously described.21 HDL cholesterol was measured in the supernatant fraction after precipitation of apo B–containing lipoproteins with heparin–manganese chloride.22 LDL cholesterol levels were estimated by the equation of Friedewald et al,23 since men with TG levels >4.5 mmol/L were excluded from the analyses. Plasma apo B levels were measured by the rocket immunoelectrophoresis method of Laurell24 as previously described.21 The coefficients of variation for cholesterol, HDL cholesterol, TG, and apo B measurements were all <3%.
Determination of LDL-PPD
Nondenaturing 2% to 16% PAGE was performed on whole plasma according to the procedures described by Krauss and Burke2 and McNamara et al.16 Gels were prepared in our laboratory as previously described.25 Aliquots of 7.5 µL of plasma samples were applied on gels in a final concentration of 20% sucrose and 0.25% bromphenol blue. After a 15-minute prerun, electrophoresis was performed at 200 V for 12 to 16 hours and at 400 V for 2 to 4 hours. Gels were stained according to standardized procedures and stored in a 9% acetic acid/20% methanol solution until analysis with an optical densitometric image analyzer (BioImage Visage 110) coupled to a SPARC Station 2 Sun computer (Millipore) and GEL 1D software. LDL-PPD was obtained from the migration of standards of known diameter such as ferritin, thyroglobulin, and 38.0-nm latex beads (Duke Scientific Corp) and plasma standards kindly provided by Dr R.M. Krauss. The estimated diameter for the major peak in each scan was identified as the LDL-PPD. One assay of LDL-PPD was performed for each subject. Analyses of pooled plasma standards revealed that the identification of the major LDL peak was highly reproducible, with an interassay coefficient of variation of <3% (unpublished data).
Statistical Analyses
LDL-PPD was measured in 103 case-control pairs. Baseline characteristics of men who developed IHD during the 5-year follow-up were compared with the characteristics of those who remained IHD-free by Student's t test for means and 
2 for frequency data. Variables with a skewed distribution were log-transformed. Associations among variables were assessed with the Pearson and Spearman correlation coefficients for parametric and nonparametric variables, respectively. Conditional logistic regression analysis was used to assess the association between risk factors and IHD. Preliminary analyses have shown that the relationship of plasma lipid, lipoprotein, and apo B to IHD was essentially linear across their distribution. These variables were therefore treated as continuous in logistic models. The association between LDL-PPD and IHD was investigated with the variable as continuous and also by categorization of the LDL-PPD distribution into three groups with the tertile values of the control group (25.64 and 26.05 nm) as cutoff points. The risk of IHD associated with each continuous variable was standardized as the relative odds of IHD for a 1-SD increase in the concentration of the variable. Risk of developing IHD during the 5-year follow-up period in men having small (LDL-PPD25.64 nm) and intermediate (25.64<LDL-PPD26.05 nm) LDL-PPDs at baseline was estimated as the relative risk of IHD compared with men having large LDL particles (LDL-PPD>26.05 nm) at baseline. Odds were adjusted for the potential confounding effects of diabetes mellitus, medication use, family history of IHD, and systolic blood pressure. Diabetes mellitus, medication use, and family history were treated as categorical variables (presence or absence), whereas systolic blood pressure was treated as continuous. Statistical analyses were all performed on SAS software (SAS Institute).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline characteristics of men who developed IHD (case patients) and who remained IHD-free during the five-year follow-up (control subjects) are presented in Table 1
. Mean age was 59±7 years, and the frequency of smokers in case patients and control subjects was identical (42%). The study design also eliminated the case-control differences in body mass index and alcohol consumption. Diabetes mellitus was more prevalent in 1985 in case patients than in control subjects (14.6% versus 1%, P<.001). The baseline prevalence of men using ß-blockers and/or diuretics on a regular basis was also higher in case patients than in control subjects (18% versus 8%, P=.02). Plasma concentrations of cholesterol, LDL cholesterol, TGs, and apo B were significantly increased in case patients compared with control subjects. Case patients were also characterized by a trend for reduced HDL cholesterol levels compared with control subjects and by a higher mean total/HDL cholesterol ratio (P=.002). Systolic blood pressure was significantly higher in case patients than in control subjects (137 versus 132 mm Hg, P=.05). Although there was a trend for smaller mean LDL-PPD in case patients than in control subjects, the difference did not reach statistical significance (P=.16). The lack of difference between case patients and control subjects in mean LDL-PPD could be attributed to the fact that a few control subjects had very low LDL-PPD (<24.2 nm). As shown in Fig 1, however, the distribution of LDL-PPD in men who did not develop IHD during follow-up tended to be shifted toward higher values compared with the IHD case patients (2 P=.03). By definition, one third of control subjects were found in each tertile of LDL-PPD. A smaller proportion of case patients (19.4%) were found within the third tertile of the LDL-PPD distribution (large LDL particles). Similar proportions of IHD case patients and control subjects were found in tertile 2, whereas the proportion of men having LDL-PPD25.64 nm was higher in case patients than in control subjects (49.5% versus 34%). As shown in Fig 2, LDL-PPD showed relatively strong associations with TG (r=-.46, P<.001), HDL cholesterol (r=.39, P<.001), and apo B levels (r=-.25, P<.001) but showed no relation to total cholesterol (r=-.03) or LDL cholesterol (r=.01) levels. Correlation coefficients were essentially similar between case patients and control subjects.
|
|
) identify the tertile values of control subjects (25.64 and 26.05 nm).
|
)-control (
) pairs.
To examine the contribution of the small, dense LDL particles to the risk of IHD, a series of multivariate logistic analyses predicting the case-control status were performed (Table 2). As illustrated in model 1, the presence of small LDL particles (LDL-PPD25.64 nm) was associated with a 3.6-fold increase in the risk of IHD (95% CI, 1.5 to 8.8) independent of the potential confounding effects of diabetes, medication use, family history of IHD, and systolic blood pressure. Further adjustment for concomitant variations in plasma LDL cholesterol (model 2), TGs (model 3), and HDL cholesterol (model 4) had very little impact on the relationship between small LDL particles and the risk of IHD. Multivariate adjustment for apo B levels (model 5) and for the total/HDL cholesterol ratio (model 6) attenuated to some extent the association between LDL-PPD and the risk of IHD, but the impact of having small LDL particles on IHD risk remained significant (2.5-fold increase in the risk of IHD; 95% CI, 1.0 to 6.6). Although no longer significant from a statistical standpoint (P=.08), the risk associated with the presence of small, dense LDL particles was not lessened when the contributions of TGs, HDL cholesterol, and apo B to the risk of IHD were simultaneously taken into account (model 7). It is also important to point out that control for the contribution of LDL-PPD did not eliminate the association between apo B, the total/HDL cholesterol ratio, and the risk of IHD, suggesting that these variables and a high proportion of small, dense LDL particles may have some impact on the risk of IHD through independent mechanisms. These multivariate analyses were also performed while tertiles of plasma lipoprotein, lipid, and apolipoprotein levels were adjusted for. Similar results were obtained, because LDL particle size remained an independent predictor of the risk of IHD after adjustment for the contribution of plasma lipid and lipoprotein levels to IHD risk when investigated as tertiles. Exclusion of diabetic individuals did not affect the relationship between the dense LDL phenotype and the risk of IHD (not shown).
|
Additional analyses were performed after 25 pairs of individuals were eliminated in which either or both the case and the control subjects were using ß-blockers or diuretics on a regular basis at the baseline evaluation. As shown in Table 3, the risk associated with the presence of small LDL particles (LDL-PPD25.64 nm) in this subsample of men not using medication remained elevated (OR, 5.1; P<.005) and was only slightly attenuated after the individual or simultaneous contributions of plasma TGs and apo B concentrations and of the total/HDL cholesterol ratio to IHD risk were controlled for.
|
Fig 3 presents the synergy between plasma apo B levels, the total/HDL cholesterol ratio, and small, dense LDL particles on the risk of IHD. Individuals with small LDL particles in the absence of elevated apo B concentrations (apo B levels <120 mg/dL, the median value of the distribution) were not at increased risk for IHD (OR, 1.0) compared with men with larger LDL particles and with relatively low apo B levels. Elevated apo B concentrations among individuals with large LDL particles resulted in a twofold increase in IHD risk, which did not reach statistical significance (P=.14), although the number of men in this particular subgroup was limited (n=32). Among these four groups, individuals having both elevated apo B levels and small LDL particles showed the greatest increase in IHD risk (OR, 6.2; 95% CI, 2.2 to 17.4; P<.001). A similar association was observed between LDL-PPD and the total/HDL cholesterol ratio, because only men with small LDL particles and with an elevated total/HDL cholesterol ratio were at greater risk of IHD (OR, 4.9; 95% CI, 1.9 to 12.7) compared with men having both large LDL particles and a ratio <6. Terms representing potential multiplicative interactions between LDL-PPD and other lipoprotein-lipid variables were tested in the multivariate model, and no interaction reached statistical significance.
|
We also investigated the relationship between the LDL-PPD as a continuous variable and the risk of IHD. A decrease of 0.65 nm (1 SD) in LDL-PPD was associated with a 35% increase in the risk of IHD (OR, 1.35; 95% CI, 0.97 to 1.89; P=.08) after adjustment for the confounding effects of diabetes, medication use, family history of IHD, and systolic blood pressure. Among lipid, lipoprotein, and apolipoprotein variables, apo B came out as the best and only significant predictor of IHD risk in multivariate stepwise logistic analyses (P=.002). LDL-PPD as a continuous variable did not contribute to the risk of IHD after the contribution of apo B levels to IHD risk had been considered.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To the best of our knowledge, the present study is the first to have investigated the relationship between LDL-PPD and the risk of IHD using a prospective design in a population-based study. Our results are in agreement with previous case-control studies that have uniformly reported an increased prevalence of small, dense LDL particles in patients with IHD.10 11 12 13 14 15 In the two largest case-control studies involving male subjects, patients with the dense LDL phenotype were characterized by a 3-fold15 and a 4.5-fold26 increase in the risk of IHD compared with those having a higher proportion of large LDL particles. In our study, men with small LDL particles (LDL-PPD
25.64 nm) at baseline were at greater risk for the subsequent development of IHD than were individuals with larger particles (3.6- and 5.1-fold increases in odds ratios, respectively, when medication users were included or excluded from the analyses), independent of nonlipid risk factors such as diabetes mellitus, family history of IHD, and elevated systolic blood pressure. The relationship of small LDL particles to IHD was also independent of age, body mass index, alcohol consumption, and smoking, the covariables used in the pairing procedure of case patients and control subjects. These results suggest that the prospective association between the LDL particle size and the risk of IHD appears to be essentially of the same magnitude as the relationship reported in previous case-control investigations.17 Mechanisms responsible for the atherogenicity of small, dense LDL particles remain largely unexplained.17 27 It has been suggested that part of the risk associated with smaller, denser LDL particles may be related to the close relationship between this phenotype and disturbances in plasma lipid levels predictive of an increased risk of IHD.6 11 17 27 The previous case-control reports that have compared the predictive value of the dense LDL phenotype with that of selected lipid and lipoprotein levels have in general concluded that the association between LDL phenotype and the risk of IHD was not independent of the concomitant variations in plasma TG, HDL cholesterol, or LDL cholesterol levels.10 12 14 15 Only one study reported a residual association between LDL particle size and risk of IHD after adjustment for plasma TG levels.13 In the present study, the dense LDL phenotype remained an independent predictor of IHD risk after control for variations in plasma TG, LDL cholesterol, and HDL cholesterol concentrations and for the total/HDL cholesterol ratio, particularly when patients using ß-blockers or diuretics were eliminated. These results suggest that the temporal association between the dense LDL phenotype and the risk of IHD may not be affected by differences in plasma lipoprotein and lipid levels at baseline and that small, dense LDL particles may increase the risk of IHD through additional mechanisms other than the concomitant variations in other atherogenic lipoproteins. It has been proposed that dense LDL may have lower binding affinity for the hepatic LDL apo B/E receptor.28 LDL subfractions of intermediate density, generally found at higher concentrations in normolipidemic individuals, bind with a higher affinity to the LDL receptor and are degraded at greater rates than the denser LDL subfractions.28 Denser LDL particles are also more susceptible to oxidation.29 30 31 The atherogenicity of dense LDL particles may also be related to their capacity for binding to the intimal proteoglycans.32
We have previously reported that the hyperapolipoprotein B dyslipidemia was more prevalent in men who eventually developed IHD.19 Apo B is secreted as VLDL by the liver and remains associated with the particle until its clearance from the circulation as IDL and LDL.33 There is systematically only one apo B per particle secreted,33 and most fasting apo B is found in the LDL fraction. For this reason, apo B concentration can be considered to be a crude marker of LDL particle number. In the present report, the risk associated with smaller LDL particles appeared to be independent of the concomitant variations in apo B concentrations and thereby of particle number (Table
s 2 and 3). Elevated apo B levels were also associated with an increased risk, independent of the LDL particle size. However, the presence of small LDL particles combined with elevated apo B concentrations resulted in the greatest increase (sixfold) in the risk of IHD (Fig 3). We also found that apo B concentration was the best metabolic predictor of IHD risk in multivariate analyses both in the present case-control analyses and in the study of the whole cohort of the Quebec Cardiovascular Study.34 These results support the hypothesis put forward by Tornvall et al11 that LDL particle number, in addition to LDL composition, may be important with respect to IHD. These results may also have rather important clinical implications. They suggest that prevention and treatment of IHD should also be focused on reducing the number of atherogenic particles rather than only altering particle size. Although favorable increases in LDL-PPD have been observed after an intensive diet and exercise training program,35 the lack of change or trivial alterations in particle size after interventions such as lipid-lowering therapy,36 37 38 diet,39 or exercise training40 may not necessarily be indicative of an inefficient treatment, particularly in situations in which plasma apo B levels are substantially reduced by such approaches.41 In this regard, a reduction in plasma apo B concentrations after a low-fat diet has been reported in subjects with the small, dense LDL phenotype.42
Summary
These prospective results from the Quebec Cardiovascular Study suggest that a significant proportion of the risk associated with the presence of small, dense LDL particles may be independent of the concomitant variations in plasma lipid concentrations. Although characterization of the LDL phenotype and the measurement of plasma lipoprotein, lipid, and apolipoprotein levels both appear to provide independent information of IHD risk, the combination of small LDL particles and elevated apo B levels represents the metabolic state most predictive of IHD.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by the National Health Research Development and Welfare Canada and by the Heart and Stroke Foundation of Canada. Dr Lamarche is a recipient of a fellowship from the Medical Research Council of Canada. Andre Tchernof is a recipient of the Fonds de Formation de Chercheurs et l'Aide a la Recherche–Fonds de Recherche en Sante de Quebec fellowship. The financial contribution of Fournier Pharma/Jouveinal is also gratefully acknowledged. We are grateful to Dr N. Michelle Robitaille for her important support in the data collection and to Paul-Marie Bernard for his helpful input regarding data analysis. The contribution of Louise Fleury is also gratefully acknowledged. We also thank the participants of the Quebec Cardiovascular Study, whose cooperation has made the study possible.
|
Footnotes |
|---|
Dr Moorjani died October 1, 1995. Received June 17, 1996; revision received August 16, 1996; accepted August 31, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792-802.[Abstract]
2. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.[Abstract]
3. Lindgren FT, Jensen LC, Wills RD, Freeman NK. Flotation rate, molecular weight and hydrated densities of the low density lipoproteins. Lipids. 1969;4:337-344.[Medline] [Order article via Infotrieve]
4. Chapman MJ, Paplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.[Abstract]
5. Swinkels DW, Hak-Lemmers HLM, Demacker PNM. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res. 1987;28:1233-1239.[Abstract]
6.
Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
7. de Graaf J, Swinkels DW, de Haan AF, Demacker PN, Stalenhoef AF. Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. Am J Hum Genet. 1992;51:1295-1310.[Medline] [Order article via Infotrieve]
8.
Swinkels DW, Demacker PNM, Hendriks JCM, van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis. 1989;9:604-613.
9.
McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.
10.
Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.
11. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67-80.[Medline] [Order article via Infotrieve]
12. Crouse JR, Parks JS, Schey HM. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985;26:566-574.[Abstract]
13. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.[Medline] [Order article via Infotrieve]
14. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.[Abstract]
15.
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
16.
McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 1987;7:483-490.
17. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 1994;5:395-403.[Medline] [Order article via Infotrieve]
18. Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, Meyer F, Rochon J. First coronary heart disease event rates in relation to major risk factors: Quebec Cardiovascular Study. Can J Cardiol. 1990;6:274-280.[Medline] [Order article via Infotrieve]
19. Lamarche B, Despres JP, Moorjani M, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol. 1995;75:1189-1195.[Medline] [Order article via Infotrieve]
20. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ishemic heart disease. N Engl J Med. 1996;334:252-257.
21. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun LD, Gagne C, Giguere M, Belanger A. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36:244-250.[Medline] [Order article via Infotrieve]
22. Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, Breckenridge C, Chow A, Kuba K, Weidman S, Arnett H, Wood P, Shlagenhaft A. Multi-laboratory comparison of three heparin-MnCl2 precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 1978;24:323-338.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.[Abstract]
24. Laurell CB. Electroimmunoassay. Scand J Clin Lab Med. 1972;124:23-27.
25. Tchernof A, Lamarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP. The dense LDL phenotype: associations with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care. 1996;19:629-637.[Abstract]
26. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990;33:532-537.[Medline] [Order article via Infotrieve]
27.
Rajman I, Maxwell S, Cramb R, Kendall M. Particle size: the key to the atherogenic lipoprotein? Q J Med. 1994;87:709-720.
28. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.[Abstract]
29.
de Graaf J, Hak Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.
30.
de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb. 1993;13:712-719.
31. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.[Abstract]
32. La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res. 1990;31:1577-1588.[Abstract]
33.
Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82:1574-1594.
34.
Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273-278.
35.
Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ. Effects of diet and exercise on qualitative and quantitative measures of LDL and its susceptibility to oxidation. Arterioscler Thromb. 1996;16:201-207.
36.
Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13:170-189.
37. Zhao SP, Hollaar L, van't Hooft FM, Smelt AHM, Leuven JAG, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIb hyperlipoproteinemia. Clin Chim Acta. 1991;203:109-118.[Medline] [Order article via Infotrieve]
38. Yuan J, Tsai MY, Hewgland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87:147-157.[Medline] [Order article via Infotrieve]
39.
Campos H, Willett WC, Peterson RM, Siles X, Bailey SM, Wilson PW, Posner BM, Ordovas JM, Schaefer EJ. Nutrient intake comparisons between Framingham and rural and urban Puriscal, Costa Rica: associations with lipoproteins, apolipoproteins, and low density lipoprotein particle size. Arterioscler Thromb. 1991;11:1089-1099.
40. Williams PT, Krauss RM, Wood PD, Lindgren FT, Giotas C, Vranizan KM. Lipoprotein subfractions of runners and sedentary men. Metabolism. 1986;35:45-52.[Medline] [Order article via Infotrieve]
41.
Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 1994;14:1569-1575.
42. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J. 1994;8:121-126.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  G. Reyes-Soffer, S. Holleran, W. Karmally, C. I. Ngai, N.-T. Chen, M. Torres, R. Ramakrishnan, W. S. Blaner, L. Berglund, H. N. Ginsberg, et al. Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus J. Lipid Res., September 1, 2009; 50(9): 1901 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Martin, A. N. Qasim, N. N. Mehta, M. Wolfe, K. Terembula, S. Schwartz, N. Iqbal, M. Schutta, R. Bagheri, and M. P. Reilly Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites Diabetes, August 1, 2009; 58(8): 1887 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Superko Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful Circulation, May 5, 2009; 119(17): 2383 - 2395. [Full Text] [PDF]
|
|
|
|
|
|
S. Mora Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use Circulation, May 5, 2009; 119(17): 2396 - 2404. [Full Text] [PDF]
|
|
|
|
 |
|
 M Lodovici, E Bigagli, G Bardini, and C. Rotella Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes Toxicology and Industrial Health, May 1, 2009; 25(4-5): 337 - 341. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Nuzum and T. Merz Macrovascular Complications of Diabetes Mellitus Journal of Pharmacy Practice, April 1, 2009; 22(2): 135 - 148. [Abstract] [PDF]
|
|
|
|
|
|
S. Mora, J. D. Otvos, N. Rifai, R. S. Rosenson, J. E. Buring, and P. M Ridker Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women Circulation, February 24, 2009; 119(7): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sam, S. Haffner, M. H. Davidson, R. B. D'Agostino Sr., S. Feinstein, G. Kondos, A. Perez, and T. Mazzone Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes Diabetes, August 1, 2008; 57(8): 2022 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Durheim, C. A. Slentz, L. A. Bateman, S. K. Mabe, and W. E. Kraus Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and visceral adiposity Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E407 - E412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Boren Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1225 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]
|
|
|
|
|
|
P. Blackburn, I. Lemieux, B. Lamarche, J. Bergeron, P. Perron, G. Tremblay, D. Gaudet, and J.-P. Despres Type 2 Diabetes Without the Atherogenic Metabolic Triad Does Not Predict Angiographically Assessed Coronary Artery Disease in Women Diabetes Care, January 1, 2008; 31(1): 170 - 172. [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Arsenault, I. Lemieux, J.-P. Despres, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study Eur. Heart J., November 2, 2007; 28(22): 2770 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell Hypertriglyceridemia N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ceska Clinical implications of the metabolic syndrome Diabetes and Vascular Disease Research, September 1, 2007; 4(3_suppl): S2 - S4. [Abstract] [PDF]
|
|
|
|
 |
|
 C. A. Slentz, J. A. Houmard, J. L. Johnson, L. A. Bateman, C. J. Tanner, J. S. McCartney, B. D. Duscha, and W. E. Kraus Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount J Appl Physiol, August 1, 2007; 103(2): 432 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. McBride Triglycerides and Risk for Coronary Heart Disease JAMA, July 18, 2007; 298(3): 336 - 338. [Full Text] [PDF]
|
|
|
|
|
|
E. Windler, M. Schoffauer, and B.-C. Zyriax The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 136 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Aznaouridis, C. Vlachopoulos, I. Dima, N. Ioakeimidis, and C. Stefanadis Triglyceride level is associated with wave reflections and arterial stiffness in apparently healthy middle-aged men Heart, May 1, 2007; 93(5): 613 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al. Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk Ann Intern Med, May 1, 2007; 146(9): 640 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shrestha, H. C. Freake, M. M. McGrane, J. S. Volek, and M. L. Fernandez A Combination of Psyllium and Plant Sterols Alters Lipoprotein Metabolism in Hypercholesterolemic Subjects by Modifying the Intravascular Processing of Lipoproteins and Increasing LDL Uptake J. Nutr., May 1, 2007; 137(5): 1165 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okazaki, S. Usui, A. Fukui, I. Kubota, and H. Tomoike Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease Clin. Chem., November 1, 2006; 52(11): 2049 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shrestha, J. S. Volek, J. Udani, R. J.Wood, C. M. Greene, D. Aggarwal, J. H. Contois, B. Kavoussi, and M. L. Fernandez A Combination Therapy Including Psyllium and Plant Sterols Lowers LDL Cholesterol by Modifying Lipoprotein Metabolism in Hypercholesterolemic Individuals J. Nutr., October 1, 2006; 136(10): 2492 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Steiner Implications of the global diabetes epidemic Diabetes and Vascular Disease Research, September 1, 2006; 3(1_suppl): S2 - S5. [Abstract] [PDF]
|
|
|
|
|
|
P. Berhanu, M. S Kipnes, M. A Khan, A. T Perez, S. F Kupfer, R. G Spanheimer, S. Demissie, and P. R Fleck Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy Diabetes and Vascular Disease Research, May 1, 2006; 3(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M Krauss, P. J Blanche, R. S Rawlings, H. S Fernstrom, and P. T Williams Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1025 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Despres Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk Eur. Heart J. Suppl., May 1, 2006; 8(suppl_B): B4 - B12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation, March 28, 2006; 113(12): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Christ, M. H Cummings, M. Stolinski, N. Jackson, P. J Lumb, A. S Wierzbicki, P. H Sonksen, D. L Russell-Jones, and A M. Umpleby Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. Eur. J. Endocrinol., March 1, 2006; 154(3): 459 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Evolving treatment paradigms for vascular risk reduction in type 2 diabetes: Report of an international symposium held in Barcelona, Spain, January 27-29, 2006 The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1_suppl): S1 - S12. [PDF]
|
|
|
|
|
|
Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Kim, S. T. Hwang, K. C. Sung, B. S. Kim, J. H. Kang, M. H. Lee, and J. R. Park Comparison of the Relationships between Serum Apolipoprotein B and Serum Lipid Distributions Clin. Chem., December 1, 2005; 51(12): 2257 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gazi, E. S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A. D. Tselepis Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma Clin. Chem., December 1, 2005; 51(12): 2264 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Inflammation, Atherosclerosis, and Aspects of Insulin Action Diabetes Care, September 1, 2005; 28(9): 2312 - 2319. [Full Text] [PDF]
|
|
|
|
|
|
M. Petersen, M. Dyrby, S. Toubro, S. B. Engelsen, L. Norgaard, H. T. Pedersen, and J. Dyerberg Quantification of Lipoprotein Subclasses by Proton Nuclear Magnetic Resonance-Based Partial Least-Squares Regression Models Clin. Chem., August 1, 2005; 51(8): 1457 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F34 - F40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. St-Pierre, B. Cantin, P. Mauriege, J. Bergeron, G. R. Dagenais, J.-P. Despres, and B. Lamarche Insulin resistance syndrome, body mass index and the risk of ischemic heart disease Can. Med. Assoc. J., May 10, 2005; 172(10): 1301 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Tzou, P. S. Douglas, S. R. Srinivasan, W. Chen, G. Berenson, and J. H. Stein Advanced Lipoprotein Testing Does Not Improve Identification of Subclinical Atherosclerosis in Young Adults: The Bogalusa Heart Study Ann Intern Med, May 3, 2005; 142(9): 742 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mackey, L. H. Kuller, K. Sutton-Tyrrell, R. W. Evans, R. Holubkov, and K. A. Matthews Hormone Therapy, Lipoprotein Subclasses, and Coronary Calcification: The Healthy Women Study Arch Intern Med, March 14, 2005; 165(5): 510 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brunzell Increased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery Disease Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 474 - 475. [Full Text] [PDF]
|
|
|
|
|
|
A. C. St-Pierre, B. Cantin, G. R. Dagenais, P. Mauriege, P.-M. Bernard, J.-P. Despres, and B. Lamarche Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Quebec Cardiovascular Study Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes and C. A Gibson Effect of Lipid-Lowering Drug Therapy on Small-Dense Low-Density Lipoprotein Ann. Pharmacother., March 1, 2005; 39(3): 523 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Charlton-Menys and P. N. Durrington Apolipoprotein A5 and Hypertriglyceridemia Clin. Chem., February 1, 2005; 51(2): 295 - 297. [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Dyslipidemia and the Metabolic Syndrome Diabetes Care, December 1, 2004; 27(12): 3009 - 3016. [Full Text] [PDF]
|
|
|
|
|
|
W. Marz, H. Scharnagl, K. Winkler, A. Tiran, M. Nauck, B. O. Boehm, and B. R. Winkelmann Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study Circulation, November 9, 2004; 110(19): 3068 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kornerup, B. G. Nordestgaard, T. K. Jensen, B. Feldt-Rasmussen, J. P. Eiberg, K. S. Jensen, and J. S. Jensen Transendothelial exchange of low-density lipoprotein is unaffected by the presence of severe atherosclerosis Cardiovasc Res, November 1, 2004; 64(2): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gonzalez-Navarro, Z. Nong, M. J. A. Amar, R. D. Shamburek, J. Najib-Fruchart, B. J. Paigen, H. B. Brewer Jr., and S. Santamarina-Fojo The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice J. Biol. Chem., October 29, 2004; 279(44): 45312 - 45321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Santamarina-Fojo, H. Gonzalez-Navarro, L. Freeman, E. Wagner, and Z. Nong Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1750 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Badzioch, R. P. Igo Jr, F. Gagnon, J. D. Brunzell, R. M. Krauss, A. G. Motulsky, E. M. Wijsman, and G. P. Jarvik Low-Density Lipoprotein Particle Size Loci in Familial Combined Hyperlipidemia: Evidence for Multiple Loci From a Genome Scan Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1942 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boden and M. Laakso Lipids and Glucose in Type 2 Diabetes: What is the cause and effect? Diabetes Care, September 1, 2004; 27(9): 2253 - 2259. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Geiss, S. Bremer, P. H. R. Barrett, C. Otto, and K. G. Parhofer In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis J. Lipid Res., August 1, 2004; 45(8): 1459 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Jensen, B. Feldt-Rasmussen, K. S. Jensen, P. Clausen, H. Scharling, and B. G. Nordestgaard Transendothelial lipoprotein exchange and microalbuminuria Cardiovasc Res, July 1, 2004; 63(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Carr and J. D. Brunzell Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2601 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lamarche and S. Desroches Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1149S - 1152S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Witte, M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis J. Lipid Res., June 1, 2004; 45(6): 1069 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Hogue, B. Lamarche, D. Gaudet, M. Lariviere, A. J. Tremblay, J. Bergeron, I. Lemieux, J.-P. Despres, C. Gagne, and P. Couture Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia J. Lipid Res., June 1, 2004; 45(6): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bosse, L. Perusse, and M.-C. Vohl Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations J. Lipid Res., June 1, 2004; 45(6): 1008 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Teerlink, P. G. Scheffer, S. J. L. Bakker, and R. J. Heine Combined data from LDL composition and size measurement are compatible with a discoid particle shape J. Lipid Res., May 1, 2004; 45(5): 954 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol N. Engl. J. Med., April 8, 2004; 350(15): 1505 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, S. B. Kritchevsky, R. P. Tracy, A. Mertens, S. M. Rubin, J. Butler, B. Goodpaster, and T. B. Harris The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort Diabetes, April 1, 2004; 53(4): 1068 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M. Georgieva, M.M.J. van Greevenbroek, R.M. Krauss, M.C.G.J. Brouwers, V.M.M.-J. Vermeulen, M.G. Robertus-Teunissen, C.J.H. van der Kallen, and T.W.A. de Bruin Subclasses of Low-Density Lipoprotein and Very Low-Density Lipoprotein in Familial Combined Hyperlipidemia: Relationship to Multiple Lipoprotein Phenotype Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 744 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bos, P. G. Scheffer, D. Vieira, J. M. Dekker, G. Nijpels, M. Diamant, T. Teerlink, C. D.A. Stehouwer, L. M. Bouter, R. J. Heine, et al. The Relationship of Lipoprotein Lipase Activity and LDL size Is Dependent on Glucose Metabolism in an Elderly Population: The Hoorn Study Diabetes Care, March 1, 2004; 27(3): 796 - 798. [Full Text] [PDF]
|
|
|
|
|
|
S. Desroches, J.-F. Mauger, L. M. Ausman, A. H. Lichtenstein, and B. Lamarche Soy Protein Favorably Affects LDL Size Independently of Isoflavones in Hypercholesterolemic Men and Women J. Nutr., March 1, 2004; 134(3): 574 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Trovati and F. Cavalot Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20. [Abstract] [Full Text]
|
|
|
|
 |
|
 G Kolovou, D Daskalova, K Anagnostopoulou, I Hoursalas, V Voudris, D P Mikhailidis, and D V Cokkinos Postprandial hypertriglyceridaemia in patients with Tangier disease J. Clin. Pathol., December 1, 2003; 56(12): 937 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Austin, K. L. Edwards, S. A. Monks, K. M. Koprowicz, J. D. Brunzell, A. G. Motulsky, M. C. Mahaney, and J. E. Hixson Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia J. Lipid Res., November 1, 2003; 44(11): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Barzilai, G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples, R. Lipton, S. Cheng, and A. R. Shuldiner Unique Lipoprotein Phenotype and Genotype Associated With Exceptional Longevity JAMA, October 15, 2003; 290(15): 2030 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K Fried and S. P Rao Sugars, hypertriglyceridemia, and cardiovascular disease Am. J. Clinical Nutrition, October 1, 2003; 78(4): 873S - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]
|
|
|
|
|
|
W. R. Archer, B. Lamarche, A. C. St-Pierre, J.-F. Mauger, O. Deriaz, N. Landry, L. Corneau, J.-P. Despres, J. Bergeron, P. Couture, et al. High Carbohydrate and High Monounsaturated Fatty Acid Diets Similarly Affect LDL Electrophoretic Characteristics in Men Who Are Losing Weight J. Nutr., October 1, 2003; 133(10): 3124 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study Diabetes Care, September 1, 2003; 26(9): 2588 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guerin, W. Le Goff, E. Frisdal, S. Schneider, D. Milosavljevic, E. Bruckert, and M. J. Chapman Action of Ciprofibrate in Type IIB Hyperlipoproteinemia: Modulation of the Atherogenic Lipoprotein Phenotype and Stimulation of High-Density Lipoprotein-Mediated Cellular Cholesterol Efflux J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3738 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, T. B. Harris, R. P. Tracy, P. Verhamme, A. B. Newman, S. M. Rubin, E. M. Simonsick, L. H. Colbert, and S. B. Kritchevsky Association of High Coronary Heart Disease Risk Status With Circulating Oxidized LDL in the Well-Functioning Elderly: Findings From the Health, Aging, and Body Composition Study Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1444 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kreisberg and A. Oberman Medical Management of Hyperlipidemia/Dyslipidemia J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2445 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Herbst, J. K. Amory, J. D. Brunzell, H. A. Chansky, and W. J. Bremner Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1112 - E1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-P. St-Onge, B. Lamarche, J.-F. Mauger, and P. J. H. Jones Consumption of a Functional Oil Rich in Phytosterols and Medium-Chain Triglyceride Oil Improves Plasma Lipid Profiles in Men J. Nutr., June 1, 2003; 133(6): 1815 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Jenkins, T. J. Lyons, D. Zheng, J. D. Otvos, D. T. Lackland, D. McGee, W. T. Garvey, R. L. Klein, and The DCCT/EDIC Research Group Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with gender and glycemia Diabetes Care, March 1, 2003; 26(3): 810 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Felmeden, C. G.C. Spencer, A. D. Blann, D. G. Beevers, and G. Y.H. Lip Low-Density Lipoprotein Subfractions and Cardiovascular Risk in Hypertension: Relationship to Endothelial Dysfunction and Effects of Treatment Hypertension, March 1, 2003; 41(3): 528 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Holmer, C. Hengstenberg, H.-G. Kraft, B. Mayer, M. Poll, S. Kurzinger, M. Fischer, H. Lowel, G. Klein, G. A.J. Riegger, et al. Association of Polymorphisms of the Apolipoprotein(a) Gene With Lipoprotein(a) Levels and Myocardial Infarction Circulation, February 11, 2003; 107(5): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Kolovou, D. Ch. Daskalova, S. A. Iraklianou, E. N. Adamopoulou, N. D. Pilatis, G. C. Hatzigeorgiou, and D. V. Cokkinos Postprandial Lipemia in Hypertension J. Am. Coll. Nutr., February 1, 2003; 22(1): 80 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Garvey, S. Kwon, D. Zheng, S. Shaughnessy, P. Wallace, A. Hutto, K. Pugh, A. J. Jenkins, R. L. Klein, and Y. Liao Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance Diabetes, February 1, 2003; 52(2): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Sattler, E. T. Schroeder, M. P. Dube, S. V. Jaque, C. Martinez, P. J. Blanche, S. Azen, and R. M. Krauss Metabolic effects of nandrolone decanoate and resistance training in men with HIV Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1214 - E1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Kraus, J. A. Houmard, B. D. Duscha, K. J. Knetzger, M. B. Wharton, J. S. McCartney, C. W. Bales, S. Henes, G. P. Samsa, J. D. Otvos, et al. Effects of the Amount and Intensity of Exercise on Plasma Lipoproteins N. Engl. J. Med., November 7, 2002; 347(19): 1483 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, J. D. Otvos, N. Rifai, and P. M Ridker Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women Circulation, October 8, 2002; 106(15): 1930 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Somekawa, H. Umeki, K. Kobayashi, S. Tomura, T. Aso, and H. Hamaguchi Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4766 - 4770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Petersen, H. Pedersen, A. Major-Pedersen, T. Jensen, and P. Marckmann Effect of Fish Oil Versus Corn Oil Supplementation on LDL and HDL Subclasses in Type 2 Diabetic Patients Diabetes Care, October 1, 2002; 25(10): 1704 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Faggin, A. Zambon, M. Puato, S. S. Deeb, S. Bertocco, S. Sartore, G. Crepaldi, A. C. Pessina, and P. Pauletto Association between the -514 c->t polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1059 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||